Who is behind this
About PeptideRank
An independent, evidence-first guide to peptide therapy — and to the telehealth market that sells it.
Why this site exists
Most of what is written about peptides is written by someone selling them. The result is a field where a rodent study becomes “clinically proven”, a mechanism becomes a result, a monthly price turns out to be a prepay rate, and the one fact a drug-tested athlete actually needs — that most of these compounds are banned in tested sport, year-round, prescription or not — is left off the page entirely. PeptideRank exists to do the boring version of that work properly: read the primary research, say plainly what has been shown in humans and what has only been shown in mice, and check the prices against the seller's own page rather than repeating them.
What we cover
Two compounds, properly: compounded tirzepatide and compounded sermorelin, and the telehealth companies that prescribe and price them. That is a deliberately narrow start. Peptide therapy is a wide field and we intend to cover more of it, but a board is only worth publishing once every price on it has been read off the seller's own page and dated — so the roster grows at the speed that work actually takes, and this page will say so plainly rather than listing compounds we have not done yet.
Who writes it
Marcus Webb researches and verifies peptide and GLP-1 telehealth provider pricing for PeptideRank, checking every claim against the provider's own published terms. The brief runs across the whole field this site covers — recovery and growth-hormone peptides, the GLP-1 drugs, the metabolic and cognitive compounds, and the clinics selling all of them. The job is narrower than it sounds and mostly unglamorous: find the actual trial, read what it measured, work out whether the outcome anyone cares about was measured at all, and write down the answer even when the answer is “nobody has tested this”. Nothing on this site is written by a company that sells what it describes, and no external party contributes copy.
How the work is done
Every provider price was read off that provider's own public page on a date we record, and “pricing not published” is printed as the finding rather than filled in with an estimate. Where a claim rests on animal or mechanism data, it is labelled separately from anything shown in people. Where a provider has a commercial relationship with us, it is placed first on a ranked list and labelled as such rather than disguised — the assessment printed beside each provider is what a commission cannot buy. The full method, including how we handle being wrong, is on the editorial policy page, and the money is set out in full on how we earn.
Corrections and contact
A source we missed, a price that has moved, a claim you think is wrong — send it. Email hello@peptiderank.org. We read everything, we fix what needs fixing, and the piece's updated date moves when we do. Nothing here is medical advice — see the medical disclaimer and talk to a licensed clinician before starting anything.